Get the Stockscreener App
0.4402
3.15%
0.0148
Sangamo Therapeutics Inc stock is traded at $0.4402, with a volume of 29.95M.
It is up +3.15% in the last 24 hours and down -26.62% over the past month.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
See More
Previous Close:
$0.4254
Open:
$0.4679
24h Volume:
29.95M
Relative Volume:
4.84
Market Cap:
$148.12M
Revenue:
$52.29M
Net Income/Loss:
$-134.84M
P/E Ratio:
-0.5869
EPS:
-0.75
Net Cash Flow:
$-117.11M
1W Performance:
+5.71%
1M Performance:
-26.62%
6M Performance:
-7.21%
1Y Performance:
-81.41%
1-Day Range:
$0.421
$0.4783
1-Week Range:
$0.4195
$0.4783
52-Week Range:
$0.3846
$2.84
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Name
Sangamo Therapeutics Inc
Sector
Industry
Phone
(510) 970-6000
Address
501 CANAL BLVD., RICHMOND, CA
Compare SGMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.4402 | 143.14M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.80 | 107.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.22 | 78.84B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
466.12 | 60.05B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.58 | 55.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.71 | 45.09B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-13-24 | Upgrade | Truist | Hold → Buy |
| Dec-10-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-28-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-21 | Resumed | Guggenheim | Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Dec-16-20 | Resumed | H.C. Wainwright | Buy |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | SunTrust | Buy |
| Aug-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-18 | Initiated | Guggenheim | Buy |
| Jun-20-18 | Initiated | BofA/Merrill | Buy |
| Nov-15-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Nov-01-16 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Oct-23-15 | Resumed | Jefferies | Buy |
| May-03-13 | Initiated | BioLogic Equity Research | Sell |
| Feb-23-11 | Reiterated | JMP Securities | Mkt Outperform |
| Jul-29-10 | Reiterated | Wedbush | Outperform |
| Oct-19-09 | Initiated | Brean Murray | Sell |
| Oct-07-09 | Reiterated | Leerink Swann | Outperform |
| Aug-25-09 | Reiterated | JMP Securities | Mkt Outperform |
View All
Sangamo Therapeutics Inc Stock (SGMO) Latest News
Sangamo Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - MarketScreener
Sangamo Therapeutics (SGMO) Surges on FDA Fast Track Designation for ST-503 - GuruFocus
Sangamo rises as FDA grants Fast Track status to neuropathic pain asset - Seeking Alpha
Sangamo (SGMO) Gains FDA Fast Track for Chronic Pain Treatment - GuruFocus
Sangamo Therapeutics secures FDA fast track for ST-503 - Traders Union
Sangamo Therapeutics receives U.S. FDA fast track designation for ST-503 - MarketScreener
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - The Manila Times
Sangamo Therapeutics (Nasdaq: SGMO) gets FDA Fast Track for ST-503 in small fiber neuropathy - Stock Titan
How Sangamo Therapeutics Inc. (GBY) stock performs in volatility spikesIndex Update & Proven Capital Preservation Methods - Newser
Can Sangamo Therapeutics Inc. (GBY) stock reach $200 price targetTrade Ideas & AI Powered Market Entry Ideas - Newser
Is Sangamo Therapeutics Inc. (GBY) stock a top hedge fund pick2025 Technical Patterns & High Yield Stock Recommendations - Newser
Earnings Report: Is Sangamo Therapeutics Inc. stock attractive for retirement portfolios2025 Top Gainers & Capital Efficient Trading Techniques - BỘ NỘI VỤ
Sangamo Therapeutics Q3 2025 Earnings Preview - MSN
Sangamo Therapeutics, Inc. (GBY.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
How Recent Developments Are Rewriting the Story for Sangamo Therapeutics - Yahoo Finance
[Form 4] SANGAMO THERAPEUTICS, INC Insider Trading Activity - Stock Titan
What drives Sangamo Therapeutics Inc. (GBY) stock priceCandlestick Trading Patterns & High Return Investment Ideas - earlytimes.in
Sangamo rises as FDA accepts rolling submission request for gene therapy - MSN
Revenues Working Against Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Following 33% Dive - simplywall.st
What analysts say about Sangamo Therapeutics Inc GBY stockDividend Yield Trends & The Smart Money Is Buying These Picks - earlytimes.in
Sangamo Therapeutics, Inc. (SGMO) Stock: Soars 9.95% on FDA Milestone for Gene Therapy - parameter.io
With cash running low, East Bay biotech Sangamo bets on FDA submission strategySan Francisco Business Times - The Business Journals
Sangamo Therapeutics Gets US FDA Approval to Begin Rolling BLA Submission for Fabry Gene Therapy - MarketScreener
Sangamo Therapeutics (SGMO) Advances Fabry Disease Therapy with FDA Rolling Submission - GuruFocus
Sangamo (SGMO) Advances Gene Therapy for Fabry Disease with FDA Approval Process - GuruFocus
FDA accepts Sangamo’s rolling BLA submission for Fabry disease gene therapy - Investing.com Canada
Sangamo Therapeutics announces FDA acceptance of BLA rolling submission request - MarketScreener
Sangamo Therapeutics Announces FDA Acceptance of Rolling Submission for Gene Therapy ST-920 for Fabry Disease Treatment - Quiver Quantitative
Sangamo stock climbs after FDA accepts BLA rolling submission request By Investing.com - Investing.com Canada
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease - The Manila Times
Sangamo (Nasdaq: SGMO) rolling ST-920 Fabry BLA accepted by FDA for accelerated review - Stock Titan
Will Sangamo Therapeutics Inc. (GBY) stock rise with strong economyWeekly Trend Report & Verified Technical Trade Signals - newser.com
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Will Sangamo Therapeutics Inc. (GBY) stock gain from green policiesQuarterly Investment Review & Safe Entry Trade Reports - newser.com
Sangamo Therapeutics (SGMO) Price Target Decreased by 20.73% to 3.32 - MSN
Real time pattern detection on Sangamo Therapeutics Inc. stockJuly 2025 Summary & Expert Approved Trade Ideas - newser.com
How buybacks impact Sangamo Therapeutics Inc. stock value2025 Retail Activity & Real-Time Volume Analysis - newser.com
How hedge fund analytics apply to Sangamo Therapeutics Inc. stockMarket Performance Recap & Consistent Profit Alerts - newser.com
Sangamo Therapeutics Inc. stock chart pattern explainedTrend Reversal & Reliable Trade Execution Plans - newser.com
Tick level data insight on Sangamo Therapeutics Inc. volatilityJuly 2025 Trends & Safe Investment Capital Preservation Plans - newser.com
Why analysts recommend Sangamo Therapeutics Inc. (GBY) stock2025 Year in Review & Fast Entry and Exit Trade Plans - newser.com
Sangamo Therapeutics Inc Stock (SGMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.73%
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):